Neutrophil extracellular trap formation is increased in psoriasis and induces human β-defensin-2 production in epidermal keratinocytes
Tóm tắt
Neutrophil extracellular traps (NETs) have been implicated in the development of certain immune-mediated diseases, but their role in psoriasis has not been clearly defined. Human β-defensin-2 (HBD-2) is an important antimicrobial peptide overexpressed in psoriasis epidermis. We evaluated whether the amount of NETs is increased in psoriasis and determined the effect of NETs on HBD-2 production in epidermal keratinocytes. Using fluorescent microscopy, we found that patients with psoriasis (n = 48) had higher amount of NETotic cells in their peripheral blood compared to healthy controls (n = 48) and patients with eczema (n = 35). Psoriasis sera showed increased ability to induce NET formation in control neutrophils but normal NET degradation ability. The amount of NETs in the peripheral blood correlated with psoriasis disease severity. NETosis was also observed in the majority (18 of 20) of psoriasis skin specimens. Furthermore, NETs induced HBD-2 mRNA and protein production in keratinocytes and immunohistochemical analysis confirmed strong expression of HBD-2 in psoriasis lesional skin. In summary, NET formation is increased in peripheral blood and lesional skin of psoriasis patients and correlates with disease severity. Additionally, NET-induced HBD-2 production may provide a novel mechanism for the decreased susceptibility of psoriasis plaques to microbial infections.
Từ khóa
Tài liệu tham khảo
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B. Jr & Reboussin, D. M. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol. 41, 401–407 (1999).
Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., Troxel, A. B. & Gelfand, J. M. Prevalence of cardiovascular risk factors in patients with psoriasis. J. Am. Acad. Dermatol. 55, 829–835 (2006).
Gisondi, P. et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br. J. Dermatol. 157, 68–73 (2007).
Su, Y. S. et al. Psoriasis as initiator or amplifier of the systemic inflammatory march: impact on development of severe vascular events and implications for treatment strategy. J. Eur. Acad. Dermatol. Venereol. 27, 876–883 (2013).
Chin, Y. Y. et al. Arthritis as an important determinant for psoriatic patients to develop severe vascular events in Taiwan: a nation-wide study. J. Eur. Acad. Dermatol. Venereol. 27, 1262–1268 (2013).
Lan, C. C. et al. Methotrexate reduces the occurrence of cerebrovascular events among Taiwanese psoriatic patients: a nationwide population-based study. Acta Derm. Venereol. 92, 349–352 (2012).
Esposito, M., Saraceno, R., Giunta, A., Maccarone, M. & Chimenti, S. An Italian study on psoriasis and depression. Dermatology 212, 123–127 (2006).
Girolomoni, G., Mrowietz, U. & Paul, C. Psoriasis: rationale for targeting interleukin-17. Br. J. Dermatol. 167, 717–724 (2012).
Sweeney, C. M., Tobin, A. M. & Kirby, B. Innate immunity in the pathogenesis of psoriasis. Arch. Dermatol. Res. 303, 691–705 (2011).
Fry, L., Baker, B. S., Powles, A. V., Fahlen, A. & Engstrand, L. Is chronic plaque psoriasis triggered by microbiota in the skin? Br. J. Dermatol. 169, 47–52 (2013).
Chowaniec, O., Jabłońska, S., Beutner, E. H., Proniewska, M., Jarzabek-Chorzelska, M. & Rzesa, G. Earliest clinical and histological changes in psoriasis. Dermatologica 163, 42–51 (1981).
Toichi, E., Tachibana, T. & Furukawa, F. Rapid improvement of psoriasis vulgaris during drug-induced agranulocytosis. J. Am. Acad. Dermatol. 43, 391–395 (2000).
Atwan, A. et al. Oral fumaric acid esters for psoriasis. Cochrane Database Syst. Rev. 8, CD010497 (2015).
Müller, S. et al. Dimethylfumarate Impairs Neutrophil Functions. J. Invest. Dermatol. 136, 117–126 (2016).
Res, P. C. et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 5, e14108 (2010).
Lin, A. M. et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J. Immunol. 187, 490–500 (2011).
Fuchs T. A. et al. Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol. 176, 231–241 (2007).
Brinkmann, V. & Zychlinsky, A. Neutrophil extracellular traps: is immunity the second function of chromatin? J. Cell Biol. 198, 773–783 (2012).
Brinkmann, V. & Zychlinsky, A. Beneficial suicide: why neutrophils die to make NETs. Nat. Rev. Microbiol. 5, 577–582 (2007).
Kaplan, M. J. & Radic, M. Neutrophil extracellular traps: double-edged swords of innate immunity. J. Immunol. 189, 2689–2695 (2012).
Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc. Natl. Acad. Sci. USA 107, 9813–9818 (2010).
Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat. Med. 15, 623–625 (2009).
Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19 (2011).
Garcia-Romo, G. S. et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra20 (2011).
Villanueva, E. et al. Netting neutrophils induce endothelial damage, infiltrate tissues and expose immunostimulatory molecules in systemic lupus erythematosus. J. Immunol. 187, 538–552 (2011).
Leffler, J. et al. Neutrophil extracellular traps that are not degraded in systemic lupus erythematosus activate complement exacerbating the disease. J. Immunol. 188, 3522–3531 (2012).
Khandpur, R. et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci. Transl. Med. 5, 178ra40 (2013).
Henseler, T. & Christophers, E. Disease concomitance in psoriasis. J. Am. Acad. Dermatol. 32, 982–986 (1995).
Morizane, S. & Gallo, R. L. Antimicrobial peptides in the pathogenesis of psoriasis. J. Dermatol. 39, 225–230 (2012).
Ong, P. Y. et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N. Engl. J. Med. 347, 1151–1160 (2002).
de Jongh, G. J. et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J. Invest. Dermatol. 125, 1163–1173 (2005).
Jansen, P. A. et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 4, e4725 (2009).
Nomura, I. et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 171, 3262–3269 (2003).
Martin, D. A. et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J. Invest. Dermatol. 133, 17–26 (2013).
Lynde, C. W., Poulin, Y., Vender, R., Bourcier, M. & Khalil, S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J. Am. Acad. Dermatol. 71, 141–150 (2014).
Gudjonsson, J. E., Thorarinsson, A. M., Sigurgeirsson, B., Kristinsson, K. G. & Valdimarsson, H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br. J. Dermatol. 149, 530–534 (2003).
Tsoi, L. C. et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 44, 1341–1348 (2012).
Nauseef, W. M. How human neutrophils kill and degrade microbes: an integrated view. Immunol. Rev. 219, 88–102 (2007).
Yu, Y. & Su, K. Neutrophil Extracellular Traps and Systemic Lupus Erythematosus. J. Clin. Cell. Immunol. 4, pii: 139 (2013).
Takahashi, H., Tsuji, H., Hashimoto, Y., Ishida-Yamamoto, A. & Iizuka, H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin. Exp. Dermatol. 35, 645–649 (2010).
Arican, O., Aral, M., Sasmaz, S. & Ciragil, P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17 and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005, 273–279 (2005).
Hwang, Y. J. et al. Serum levels of LL-37 and inflammatory cytokines in plaque and guttate psoriasis. Mediators Inflamm. 2014, 268257 (2014).
Martinelli, S. et al. Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J. Biol. Chem. 279, 44123–44132 (2004).
Wartha, F., Beiter, K., Normark, S. & Henriques-Normark, B. Neutrophil extracellular traps: casting the NET over pathogenesis. Curr. Opin. Microbiol. 10, 52–56 (2007).
Branzk, N. & Papayannopoulos, V. Molecular mechanisms regulating NETosis in infection and disease. Semin. Immunopathol. 35, 513–530 (2013).
Nestle, F. O. et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J. Exp. Med. 202, 135–143 (2005).
Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 449, 564–569 (2007).
Skrzeczynska-Moncznik, J. et al. Secretory leukocyte proteinase inhibitor-competent DNA deposits are potent stimulators of plasmacytoid dendritic cells: implication for psoriasis. J. Immunol. 189, 1611–1617 (2012).
Harder, J., Bartels, J., Christophers, E. & Schröder, J. M. A peptide antibiotic from human skin. Nature 387, 861 (1997).
Hollox, E. J. et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat. Genet. 40, 23–25 (2008).
Huh, W. K. et al. Dynamic alteration of human beta-defensin 2 localization from cytoplasm to intercellular space in psoriatic skin. J. Mol. Med. (Berl). 80, 678–684 (2002).
Liu, A. Y. et al. Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria and the state of differentiation. J. Invest. Dermatol. 118, 275–281 (2002).
Yang, D. et al. Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286, 525–528 (1999).
Niyonsaba, F., Ogawa, H. & Nagaoka, I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 111, 273–281 (2004).
Harder, J. et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J. Invest. Dermatol. 130, 1355–1364 (2010).
Naldi, L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. Clin. Dermatol. 28, 67–72 (2010).